Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
ORGANIZATION
Pharma Biz Leader Airs Concern over Effective Tax Hikes
Daiichi Sankyo President Joji Nakayama voiced his apprehension on January 7 over the ruling parties’ taxation reform plan for the next fiscal year, saying that it would be tantamount to a tax hike for some drug makers. The tax reform…
To read the full story
Related Article
- Pharma Leader Nakayama Hails Tax Plan, Says His New Year Remarks Misleading
January 15, 2015
- Ruling Parties Settle on 25%-Plus-5% Cap for R&D Tax Credit
January 5, 2015
ORGANIZATION
- JPMA to Launch Nitrosamine Risk Project for APIs in FY2026
April 15, 2026
- Labor Group Chief Pushes Fundamental Drug Pricing Reform Ahead of Honebuto
April 8, 2026
- Drug Makers Step Up Self-Inspections for Supply Stability: FPMAJ Survey
April 8, 2026
- Pharma Labor Group Sees Wage Hikes in Low 4% Range as Talks Continue
April 7, 2026
- Generic Use Rate Hits 90% for First Time in October-December: JGA
April 7, 2026
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…